Full View

Pathophysiology of Target‐Organ Disease: Does Angiotensin II Remain the Key?

RG Victor - The Journal of Clinical Hypertension, 2007 - Wiley Online Library
Basic research provides an increasingly compelling rationale for renin‐angiotensin system
(RAS) blockade in hypertension treatment and cardiovascular risk reduction. Clinical trials …
被引用次数：17 相关文章

Pathophysiology of target-organ disease: does angiotensin II remain the key?

RG Victor - Journal of clinical hypertension (Greenwich …, 2007 - pubmed.ncbi.nlm.nih.gov
Basic research provides an increasingly compelling rationale for renin-angiotensin system
(RAS) blockade in hypertension treatment and cardiovascular risk reduction. Clinical trials …
[HTML] nih.gov

[HTML][HTML] Pathophysiology of Target‐Organ Disease: Does Angiotensin II Remain the Key?

RG Victor - The Journal of Clinical Hypertension, 2007 - ncbi.nlm.nih.gov
Basic research provides an increasingly compelling rationale for renin‐angiotensin system
(RAS) blockade in hypertension treatment and cardiovascular risk reduction. Clinical trials …

Pathophysiology of target-organ disease: does angiotensin II remain the key?

RG Victor - Journal of Clinical Hypertension (Greenwich, Conn.), 2007 - europepmc.org
Basic research provides an increasingly compelling rationale for renin‐angiotensin system
(RAS) blockade in hypertension treatment and cardiovascular risk reduction. Clinical trials …

[引用][C] Pathophysiology of target-organ disease: Does angiotensin II remain the key?

G VICTOR - The Journal of clinical hypertension, 2007 - Wiley